BRAF and thyroid cancer, nonmedullary, 2: Genetic analysis revealed that PTC primarily exhibited the BRAF V600E mutation (47 out of 66 PTC cases, 71.2%), whereas FTC exclusively showed RAS mutations (three out of three FTC cases, 100%).